| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 1.04M | 1.23M | 1.41M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | -1.04M | -1.23M | -1.41M | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -0.19% | -0.14% | 1% | - | - | - |
| Operating Expenses | 17.4M | 35.53M | 52.92M | 88.18M | 103.67M | 232.26M | 468.04M | 569.55M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.05M | 5.39M | 7.31M | 14.61M | 25.26M | 39.81M | 60.7M | 92.9M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 12.79M | 30.14M | 45.61M | 73.56M | 78.41M | 169.45M | 332.34M | 476.64M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 5.18M | 0 | 0 | 0 | 23M | 75M | 0 |
| Operating Income | -17.83M | -35.53M | -54.15M | -89.58M | -103.67M | -232.26M | -468.04M | -569.55M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -0.99% | -0.52% | -0.65% | -0.16% | -1.24% | -1.02% | -0.22% |
| EBITDA | -17.21M | -34.5M | -52.92M | -88.18M | -100.21M | -222.8M | -457.87M | -553.7M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -1% | -0.53% | -0.67% | -0.14% | -1.22% | -1.06% | -0.21% |
| D&A (Non-Cash Add-back) | 625K | 1.04M | 1.23M | 1.41M | 3.46M | 9.45M | 10.17M | 15.85M |
| EBIT | -17.83M | -29.41M | -50.23M | -89.21M | -100.07M | -223.48M | -402.27M | -463.93M |
| Net Interest Income | 0 | 828K | 592K | 237K | 337K | 8.35M | 62.91M | 109.99M |
| Interest Income | 164K | 903K | 632K | 244K | 344K | 8.36M | 62.91M | 109.99M |
| Interest Expense | 0 | 75K | 40K | 7K | 7K | 2K | 0 | 0 |
| Other Income/Expense | 595K | 6.05M | 3.88M | 364K | 3.59M | 8.77M | 65.78M | 105.62M |
| Pretax Income | -17.24M | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -17.24M | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -0.71% | -0.71% | -0.77% | -0.12% | -1.23% | -0.8% | -0.15% |
| Net Income (Continuing) | -17.24M | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.83 | -8.12 | -14.10 | -2.97 | -1.93 | -3.44 | -4.14 | -3.80 |
| EPS Growth % | - | -0.68% | -0.74% | 0.79% | 0.35% | -0.78% | -0.2% | 0.08% |
| EPS (Basic) | -4.84 | -8.12 | -14.10 | -2.97 | -1.93 | -3.44 | -4.14 | -3.80 |
| Diluted Shares Outstanding | 3.57M | 3.63M | 3.8M | 29.55M | 51.92M | 64.88M | 97.16M | 122M |
| Basic Shares Outstanding | 3.56M | 3.63M | 3.79M | 29.55M | 51.92M | 64.88M | 97.16M | 122M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 36.35M | 66.67M | 61.72M | 389M | 256.35M | 942.55M | 1.1B | 1.79B |
| Cash & Short-Term Investments | 36.14M | 66.09M | 58.98M | 386.2M | 245.97M | 931.38M | 1.08B | 1.75B |
| Cash Only | 36.14M | 66.09M | 58.98M | 386.2M | 68.98M | 834.66M | 397.45M | 387.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 176.99M | 96.72M | 682.78M | 1.36B |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 3.61M | 20.66M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 5.96M | 20.11M |
| Total Non-Current Assets | 3.28M | 4.13M | 3.98M | 3.82M | 67.99M | 63.62M | 311.96M | 1.72B |
| Property, Plant & Equipment | 2.97M | 3.41M | 3.39M | 3.27M | 35.91M | 31.65M | 110.62M | 270.15M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 27.12M | 26.55M | 162.68M | 1.39B |
| Other Non-Current Assets | 311K | 723K | 584K | 550K | 4.96M | 5.43M | 38.66M | 65.68M |
| Total Assets | 39.63M | 70.8M | 65.7M | 392.83M | 324.34M | 1.01B | 1.41B | 3.51B |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | - | 0.79% | -0.07% | 4.98% | -0.17% | 2.1% | 0.4% | 1.49% |
| Total Current Liabilities | 4.26M | 6.71M | 11.05M | 46.86M | 28.72M | 40.52M | 145.34M | 140.18M |
| Accounts Payable | 1.81M | 2.83M | 3.38M | 29.79M | 6.76M | 9.79M | 14.59M | 48.45M |
| Days Payables Outstanding | - | 996.09 | 1K | 7.74K | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | -297K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 850K | 2.4M | 433K | 298K | 3.46M | 1.18M | 11.06M | 20.55M |
| Current Ratio | 8.53x | 9.93x | 5.58x | 8.30x | 8.93x | 23.26x | 7.54x | 12.75x |
| Quick Ratio | 8.53x | 9.93x | 5.58x | 8.30x | 8.93x | 23.26x | 7.54x | 12.75x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.43M | 121.82M | 161.02M | 122K | 11.6M | 12.04M | 22.11M | 65.32M |
| Long-Term Debt | 3.76M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 458K | 161K | 0 | 0 | 11.51M | 12.03M | 22.11M | 65.22M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 212K | 121.66M | 161.02M | 122K | 96K | 9K | 0 | 100K |
| Total Liabilities | 8.69M | 128.53M | 172.07M | 46.98M | 40.32M | 52.56M | 167.45M | 205.5M |
| Total Debt | 4.5M | 458K | 161K | 0 | 16.78M | 17.94M | 29.22M | 71.11M |
| Net Debt | -31.64M | -65.63M | -58.81M | -386.2M | -52.2M | -816.72M | -368.23M | -316.77M |
| Debt / Equity | 0.15x | - | - | - | 0.06x | 0.02x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -473.77x | -1353.83x | -12797.29x | -14810.00x | -116128.00x | - | - |
| Total Equity | 30.94M | -57.73M | -106.37M | 345.84M | 284.02M | 953.61M | 1.24B | 3.31B |
| Equity Growth % | - | -2.87% | -0.84% | 4.25% | -0.18% | 2.36% | 0.3% | 1.66% |
| Book Value per Share | 8.68 | -15.90 | -28.03 | 11.71 | 5.47 | 14.70 | 12.77 | 27.10 |
| Total Shareholders' Equity | 30.94M | -57.73M | -106.37M | 345.84M | 284.02M | 953.61M | 1.24B | 3.31B |
| Common Stock | 6K | 6K | 7K | 54K | 56K | 82K | 98K | 128K |
| Retained Earnings | -29.59M | -59.07M | -109.35M | -198.56M | -298.64M | -522.13M | -924.39M | -1.39B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1.75M | 0 | 0 | -241K | -361K | 179K | -3.87M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.96K | -30.47M | -47.15M | -46.63M | -121.39M | -170.6M | -296.79M | -452.63M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -2035.09% | -0.55% | 0.01% | -1.6% | -0.41% | -0.74% | -0.53% |
| Net Income | -17.24K | -29.48M | -50.27M | -89.22M | -100.08M | -223.49M | -402.27M | -463.93M |
| Depreciation & Amortization | 625 | 1.04M | 1.23M | 1.41M | 3.46M | 9.45M | 10.17M | 15.85M |
| Stock-Based Compensation | 390 | 749K | 1.19M | 5.43M | 10.73M | 23.65M | 48.76M | 84.82M |
| Deferred Taxes | 0 | 51K | 0 | 301K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 260 | -4.71M | -3.2M | 179K | 1.5M | 7.05M | -34.77M | -34.47M |
| Working Capital Changes | 1K | 1.9M | 3.91M | 35.27M | -37.01M | 12.74M | 81.32M | -54.9M |
| Change in Receivables | 0 | 1.27M | 868K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | -1.19M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 1.27M | 868K | 26.1M | -12.47M | 2.9M | 11.22M | 34.58M |
| Cash from Investing | -1.12K | -1.77M | -1.2M | -1.1M | -212.31M | 74.58M | -773.31M | -2.01B |
| Capital Expenditures | -1.22K | -1.77M | -1.2M | -1.16M | -6.55M | -5.84M | -67.88M | -22.43M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 106 | 1K | 0 | 0 | 26K | 0 | 0 | -96.73M |
| Cash from Financing | 43.86K | 62.19M | 41.57M | 374.87M | 17.8M | 861.55M | 639.81M | 2.45B |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 231.86K | 128K | -655K | 1.04M | 3.9M | 5.07M | 3.77M | 12.85M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -16.18K | -32.24M | -48.34M | -47.78M | -127.95M | -176.44M | -364.67M | -475.05M |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -1990.97% | -0.5% | 0.01% | -1.68% | -0.38% | -1.07% | -0.3% |
| FCF per Share | -0.00 | -8.88 | -12.74 | -1.62 | -2.46 | -2.72 | -3.75 | -3.89 |
| FCF Conversion (FCF/Net Income) | 0.00x | 1.03x | 0.94x | 0.52x | 1.21x | 0.76x | 0.74x | 0.98x |
| Interest Paid | 0 | 0 | 40K | 0 | 7K | 2K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.72% | - | - | -74.51% | -31.78% | -36.12% | -36.67% | -20.41% |
| Return on Invested Capital (ROIC) | - | - | - | - | -81.22% | -94.49% | -69.57% | -22.13% |
| Debt / Equity | 0.15x | - | - | - | 0.06x | 0.02x | 0.02x | 0.02x |
| Interest Coverage | - | -473.77x | -1353.83x | -12797.29x | -14810.00x | -116128.00x | - | - |
| FCF Conversion | 0.00x | 1.03x | 0.94x | 0.52x | 1.21x | 0.76x | 0.74x | 0.98x |
| 2020 | 2021 | |
|---|---|---|
| Pneumococcal Conjugate Vaccine | 7B | 7B |
| Pneumococcal Conjugate Vaccine Growth | - | 0.00% |
Vaxcyte, Inc. (PCVX) grew revenue by 0.0% over the past year. Growth has been modest.
Vaxcyte, Inc. (PCVX) reported a net loss of $657.2M for fiscal year 2024.
Vaxcyte, Inc. (PCVX) has a return on equity (ROE) of -20.4%. Negative ROE indicates the company is unprofitable.
Vaxcyte, Inc. (PCVX) had negative free cash flow of $591.5M in fiscal year 2024, likely due to heavy capital investments.